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Nephrotoxicity, high frequency ototoxicity, efficacy and
serum kinetics of once versus thrice daily dosing of netilmicin
in patients with serious infections
J. Blasei**, H. P. Simmen', U. Thurnheer*, C. Konig* and R. Lathy*
"Department of Medicine, D POL 40, University Hospital Zurich, CH-8091 Zurich,
Switzerland; bAnna Seiler Haus, Inselspital Berne, Berne, Switzerland
The effect of dosing regimen on nephrotoxicity, high frequency ototoxicity,
efficacy and serum kinetics was studied in a prospective, randomised clinical study.
Therapy was started with total daily doses of 6 mg/kg given once (od) or thrice (tid)
daily to 56 and 57 patients, respectively. Subsequent doses were adjusted according
to serum levels. No major differences in toxicity or efficacy were noticed between od
and tid regimens: clinical failures occurred in two and two patients, four and five
patients suffered from a decrease of ^ 20 dB at least unilaterally at one frequency
between 8 and 18 kHz, six and seven patients had a >25 /jmol/L or > 2 5 % increase
in serum creatinine, respectively. Serum creatinine or creatinine clearance did not
change significantly during either therapy. Major differences between the two study
groups were limited to pharmacokinetic parameters. Od dosing resulted in higher
peak (mean of 21.6 vs 7.2 mg/L) and lower trough levels (0.5 vs 1.4mg/L).
Half-lives of netilmicin determined between 1 and 8 h increased significantly
during therapy with tid (from a mean of 2.75 to a mean of 3.33 h, /><0.01) but not
significantly with od (rise from 2.8 to 3.03 h). Much longer half-lives were determined
between 8 and 24 h in the od group (mean of 5.7 h, /><0.01). In conclusion, only
minimal differences in toxicity and efficacy were observed. Their clinical relevance
appears to be minimal.
Introduction
For several decades aminoglycoside antibiotics have been administered as multiple daily
dosing regimens. An increasing number of experimental and clinical studies nowadays
suggests that once daily dosing regimens (od) might be at least as efficacious and not more
or possibly even less toxic (Bennett et al., 1979; Powell et al., 1983; Craig, Redington &
Ebert, 1991; Gilbert, 1991; Prins et al., 1993; EORTC, 1993).
This clinical trial compared single versus thrice daily (tid) administration of netilmicin
in seriously ill patients. Pharmacokinetics, nephrotoxicity, high frequency ototoxicity,
clinical and bacteriological efficacy were considered in a prospective, randomised, open
trial performed in two Swiss Hospitals.
*Tel: +41-(1)-2553618; Fax: +41-{l)-2554562.
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Patients & methods
Patients
Patients aged ^ 16 years with suspected or verified bacterial infections serious enough to
require aminoglycoside therapy were eligible. Informed consent was obtained. Exclusion
criteria were: (1) known allergy to aminoglycosides, (2) pregnancy, (3) treatment with an
aminoglycoside within the preceding 4 weeks, (4) previous enrolment in the study, (5)
renal impairment (initial serum creatinine > 130 /imol/L) and (6) known reduced auditory
function. 94 patients were treated in the Departments of Medicine and Surgery at the
University Hospital in Zurich, 19 patients were treated at the Anna Seiler Haus,
Inselspital, Berne, Switzerland.
Antibiotic therapy
All patients (except one tid-treated patient) received netilmicin in combination with at
least one other antibiotic (Table I). Patients were randomised in a prospective study to
receive initial daily doses of netilmicin of 6 mg/kg either as a single daily dose or as three
divided doses. Netilmicin was given as an intravenous infusion over 60 min. Serum
samples of netilmicin were collected during the second day of treatment and thereafter
every two to three days. Samples were obtained immediately at the end of the 1 h-infusion,
8 h after the onset of the infusion and also after 24 h for the od regimens. Doses were
adjusted whenever 8 h levels were outside the target range of 1.5-6 mg/L and 0.5-2 mg/L
for od and tid regimens, respectively (Blaser et al., 1994). Peak levels of 18-24 mg/L and
6-8 mg/L were considered optimal for od and tid regimens, respectively.
Netilmicin assay
Netilmicin serum concentrations were measured by fluorescence polarisation assay (TDx,
Abbott Laboratories). The coefficient of variation of the assay was <10% for
concentrations of > 1 mg/L (Joos, Luthy & Blaser, 1989). Spiked specimens of 0.5, 0.25
and Omg/L were measured as 0.52 ±0.03, 0.31 ±0.04 and 0.07 ±0.06 mg/L
(mean ± standard deviation), respectively.
Evaluation of nephrotoxicity
An initial serum creatinine was measured before or at onset of therapy, every second
or third day during therapy and finally on day one or two after cessation of therapy.
In addition, 24 h-creatinine-clearance was also determined when possible, both at the
beginning of therapy and also one or two days after completion of therapy. Urine was
collected over a 24 h period and serum creatinine measured within this period.
Nephrotoxicity was defined as an increase of the final serum creatinine of > 25 /imol/L
or 25% above the initial value or a decrease in creatinine clearance of > 25 mL/min or
25 % below the initial measurement (Blaser etal.,\ 994). Threshold values applied by other
investigators to define nephrotoxicity reach from a serum creatinine increase of > 15%
to £50% (Nordstrom et al., 1990; de Vries et al., 1990).
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Evaluation of auditory toxicity
Auditory function was monitored where possible during treatment by high frequency
audiometry (Interacoustics High Frequency Audiometer Model AS 10 HF) at 8, 10, 12,
14,16 and 18 kHz. The audiometry was performed at the bedside with alert patients only.
Some patients, however, were too ill to allow for a reliable audiometry. Any disturbing
noises were avoided within the room while audiometry was carried out. Change of
auditory function during therapy was determined as a difference between the initial and
final assessment of the auditory thresholds. Auditory toxicity was denned as an increase
of ;> 20 dB in auditory threshold at least unilaterally at one frequency.
The quality of the audiometry tests was assessed in a control study in which 13 healthy
volunteers were enrolled, to document the variability of the measurement of the hearing
threshold not induced by the administration of any ototoxic compounds. Four
audiometries were performed per volunteer within a month, two in a quiet room and
another two with distracting background noises (an audio tape with a comedy show,
including a lot of laughter).
Microbiology
Samples of blood, sputum, abscess material, drainage fluids or urine were taken before
start of netilmicin treatment and, where feasible, during and after completion of therapy.
Identification of pathogens and susceptibility testing according to standard techniques
was done at the Institutes for Medical Microbiology of the Universities of Zurich and
Berne.
Evaluation of clinical and bacteriological response
A patient's clinical response was considered satisfactory if (1) clinical signs or symptoms
of infection resolved or improved or (2) the bacterial pathogens, whenever isolated, were
eradicated. In contrast, a patient's course was considered unsatisfactory if (1) clinical signs
or symptoms of the infection persisted or deteriorated, (2) a relapse occurred after initial
improvement or (3) the patient died due to infection. A patient's course was classified
indeterminate if (1) an initially presumed bacterial infection was ruled out during
follow-up, (2) an infection was caused by a pathogen resistant to netilmicin already at
start of treatment or if (3) there was a serious non-infectious underlying disease which
did not allow for a clinical evaluation of the effect of the antibiotic therapy. The
bacteriological response was classified as elimination, when follow-up cultures remained
sterile, persistence or relapse, when the cultures remained positive for the same organisms
or when these organisms were cultured again after discontinuation of treatment,
respectively. When specimens for follow-up cultures were not available because of clinical
cure, bacteriological response was classified as indeterminate.
Statistical analysis
The volume of distribution was calculated as the ratio between administered dose and
the difference between peak and trough concentrations. Half-lives were calculated
according to an exponential decline between two concentrations. For comparison of the
two groups the Mann-Whitney U test and the contingency test were used for analysis of
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Table I. Antibiotic combinations including netilmicin
Netilmicin
in
Dual combination with
penicillin
cephalosporin
various
Triple combination with
penicillin + imidazole
penicillin + various
cephalosporin + various
Total combinations
od
30
8
3
13
3
5
62
tid
32
2
1
19
2
4
60
P°
0.72
0.11
0.63
0.26
0.97
0.96
'Contingency table with continuity correction.
continuous or categorical variables, respectively. Changes in clinical parameters during
therapy within one treatment group were analysed by the Wilcoxon signed rank test. All
statistical calculations were performed with the program StatViewII, Abacus Concepts,
Berkeley, California. All significance probabilities were calculated for the two-tailed tests.
Results
Patients
A total of 113 patients, 56 od-treated patients and 57 tid-treated patients, were
randomised. The two treatment groups were comparable with respect to sex, age, weight,
temperature and arterial pressure (Table II). One third of all patients had abdominal
infections (Table III). The distribution of infection sites did not differ statistically between
both groups. The groups were also comparable with respect to the bacterial pathogens.
Gram-positive and -negative organisms were found at similar frequencies in patients from
which a single pathogen could be isolated (Table IV). All patients except one tid-treated
patient received netilmicin in combination with at least one other antibiotic (Table I). In
16 of 17 combinations included cephalosporins, either ceftriaxone or ceftazidime, while
one patient received two first generation cephalosporins, cefoxitin and cephradine,
consecutively. In each treatment group netilmicin was administered in combination with
vancomycin in three patients. In both groups, two of these three patients received a
Table n. Baseline clinical characteristics
Evaluable patients
Male/female
Age (year)*
Temperature (°C)*
Arterial pressure (mmHg)"
Weight (kg)-
od
56
44/12
48 (19-82)
38.3 (36.4-40.6)
120/70
69 (47-110)
tid
57
37/20
48 (17-84)
38.4 (36.2-41.0)
120/70
65(40-111)
P
0.16"
0.4CK
0.37'
0.98'
0.08'
•Median (range).
•Contingency table with continuity correction.
'Mann-Whitney U test.
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Table III. Primary infection site
Abdomen
Uro-genital tract
Respiratory tract
Endocarditis
Bacteraemia
Unexplained fever*
Various
Total
od
18
8
6
10
5
4
5
56
tid
21
2
10
5
2
13
4
57
P-
0.74
0.09
0.44
0.25
0.42
0.04
0.98
•Contingency table with continuity correction.
'Patients in aplasia after chemotherapy for
leukaemia, non-Hodgkin-lymphoma or other tu-
cephalosporin as a third antibiotic. Thirteen and ten patients also received a furosemide
in the od- and tid-treatment group, respectively. No statistically significant differences
were observed between the treatment groups with respect to combinations with other
antibiotics or with furosemide.
Dosing and serum kinetics of netilmicin
Initial daily doses of netilmicin were not significantly different for the two groups
(Table V). On an average the mean daily dose was reduced during therapy by 5.7% for
od and 10.3% (/><0.05) for tid. Median (and range) of the initial and final dose during
od-dosing were 400 mg (280-500) and 400 mg (130-600) and during tid-dosing 360 mg
(210-600) and 360 mg (150-600), respectively. Thereby, the final daily dose of the
tid-regimen was significantly lower than that of the od-regimen. No statistical differences
between the two treatment groups were observed with respect to the cumulative dose or
Table IV. Microbiology
Single pathogen
Staphylococcus aurens
Coagulase-negative
Staphylococci
Streptococci
Escherichia coli
Pseudomonas aeruginosa
Other
Polymicrobial
with anaerobes
without anaerobes
No growth
Total
od
21
4
2
3
3
2
7
15
9
6
20
56
tid
14
5
0
0
3
4
2
14
6
8
29
57
P°
0.20
0.96
0.15
"Contingency table with continuity correction.
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Table V. Treatment characteristics
Evaluable patients
Total daily dose (mg)
initial
final
Total cumulative dose
Duration of treatment
(mg)
(days)
406
383
3178
8.5
od
56
(±66)*
(±104)
(±1836)
(±4.9)
379
340
3331
10
tid
57
(±83)
(±98^
(±2245)
(±6.9)
P"
0.07
0.02
0.92
0.14
'Mann-Whitney U test.
*Mean(±s.D.)
'Significant differences between initial and final values within one treatment group as
calculated by Wilcoxon signed-rank test, P<0.05.
the duration of therapy. Median duration (range) of od and tid treatment were 7 days
(3-25) and 8 days (3-39), respectively.
Three-fold higher peak levels of netilmicin were obtained with the od regimen
(Table VI). Also 8 h levels were significantly higher during od dosing. On an average the
24 h troughs during od treatment were still 39% of the 8 h troughs observed during tid
dosing. For both regimens only the trough levels increased significantly during therapy.
Volumes of distribution were similar in both study groups as well as the half-lives
observed between 1 h and 8 h. During tid therapy mean half-lives increased significantly
by 21%, whereas no significant increase (8%) occurred with od therapy. Remarkably
longer half-lives were determined within the 8 to 24 h period of the od regimen. On an
average these half-lives were 93% longer compared to those observed within the first 8 h
of the 24 h dosing interval (P< 0.001), (Table VII).
Toxicity
Changes between the initial and final serum creatinine concentrations were determined
in 112 of the 113 patients enrolled (Table VIII). The patients in the tid group had lower
serum creatinine levels at the onset of therapy whereas no significant differences were
Table VI. Serum levels of netilmicin
Evaluable patients
Scrum levels
peak
8-h level
24-h level
(mg/L)
initial
final
initial
final
initial
final
22.1
21.1
3.58
3.68
0.46
0.60
od
42
(±1.0?
(±6.2)
(±2.35)
(±1.47)
(±0.51)
(±0.77)<
7.35
7.04
1.23
1.48
tid
53
(±2.70)
(±1.91)
(±0.83)
(±0.73^
P*
<0.001
<0.001
<0.001
<0.001
•Mann-Whitney U test.
'Mean (±S.D.).
'Significant difference between initial and final values within one treatment group as
calculated by Wilcoxon signed-rank test; /><0.05.
Once vs thrice daily dosing of netilmicin 809
Table VII. Serum kinetics of netilmicin
Evaluable patients
Volumes of distribution
Half-lives (h)
between 1 and 8
between 8 and 24
between 1 and 24
(L)
initial
final
initial
final
initial
final
initial
final
20.4
19.8
2.84
3.03
5.29
6.04
3.96
4.57
od
42
(±6.4)'
(±6.0)
(±1.17)
(±1.33)
(±1.33)
(±3.56)
(±0.91)
(±2.29)'
23.3
21.8
2.75
3.33
tid
53
(±10.2)
(±7.2)
(±0.86)
(±1.26y
P°
0.26
0.26
0.96
0.17
•Mann-Whitney U-test.
'Mean (±S.D.).
'Significant difference between initial and final values within one treatment group as
calculated by Wilcoxon signed-rank test; P<0.05.
present at the end of therapy. Also, no significant changes of serum creatinine were
observed between initial and final values within each study group. However, a total
of 13 patients, six and seven patients in the od and tid treatment group, respectively,
experienced an increase of serum creatinine of >25% or 25 //mol/L. In each group,
one of these patients received frusemide. Netilmicin was combined with a penicillin
in ten of these 13 patients. A serum creatinine increase of > 100% was documented
in two patients in either treatment group. Three of these received netilmicin plus a
penicillin, the fourth received a combination of netilmicin, amoxycillin, imidazole and
frusemide.
Initial and final 24 h creatinine clearance data were available for 30 od- and 27
tid-treated patients only (Table IX). No significant changes in clearance occurred during
treatment within each study group. Also, no significant differences of the clearance rates
were present between both groups at the onset or at the end of treatment. However, 37%
Table VIII. Serum creatinine
Evaluable patients
Serum creatinine Qimol/L)
initial
final
Change of serum creatinine
during therapy
number of patients with an increase
^ 2 5 %
> 2 5 %
od
55
97(52-133)*
94 (47-410)
49
6
tid
57
87(50-118)
85 (60-203)
50
7
P
0.03"
0.22*
0.95'
•Median (range).
'Mann-Whitney U test.
'Contingency table with continuity correction.
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Table IX. Creatinine clearance
Evaluable patients
Creatinine clearance (mL/min)
initial
final
Change of creatinine clearance
during therapy
number of patients with an decrease
<;25%
>25%
od
30
92 (21-216)°
95 (20-183)
19
11
tid
27
83 (31-177)
83 (32-144)
20
7
P
0.88"
0.56"
0.56'
'Median (range).
'Mann-Whitney U test.
'Contingency table with continuity correction.
and 26% of od and tid treated patients, respectively, experienced a decrease of creatinine
clearance of >25% (P = 0.56).
Initial and final audiometric data were available for 38 od and 47 tid patients (Table X).
In each group 11% of the patients monitored suffered from a hearing loss ^20 dB at
least unilaterally, at one frequency. A total of 336 and 441 threshold differences of
initial and final audiometries were analysed for the od and tid treated patients,
respectively. The median changes in auditory function was 0 dB in both groups. There
was, however, a statistically but not clinically significant difference in the mean changes,
since auditory function improved by 0.3 and 1.7 dB for od and tid regimen, respectively.
None of the patients in either group experienced a hearing loss at any frequency of
>25 dB. Control audiometries with healthy volunteers documented that 91% of 468
differences in the hearing threshold between a baseline audiometry and a second
assessment with or without distracting noises were within the range of + 10 and — 10 dB.
In less than 2% a difference of ;> 20 dB was observed in the volunteers, compared to 11 %
in the patients.
Table X. High frequency audiometry*
Evaluable patients
Number of patients with
reduction ^20 dB4
Change in auditory function
(A dB)'
median/mean (±S.D.)
od
38
4(11%)
0/0.3 (±8.0)
tid
47
5(11%)
0/1.7 (±8.5)
0.74'
0.001'
•Frequencies: 8, 10, 12, 14, 16 and 18 kHz.
'At least unilateral, at one frequency.
'Differences between final minus initial measurement per ear and frequency (n = 336 for od, n = 441
for tid).
^Contingency table with continuity correction.
'Mann-Whitney U test.
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Table XI. Clinical and bacteriological outcome
Clinical outcome
satisfactory
unsatisfactory
indeterminate
Bacteriological outcome
with growth
elimination
persistence/relapse
indeterminate
no growth
od
56
41
2
13
36
11
3/1
21
20
tid
57
36
2
19
28
11
5/0
12
29
0.70
0.91
•Contingency table with continuity correction.
Evaluation of clinical and bacteriological response
Clinical response to therapy could be evaluated in 43 of the 56 od and 38 of the 57 tid
patients (Table XI). In each netilmicin treatment group two treatments were classified as
unsatisfactory. Abdominal surgery has been performed before antibiotic treatment in all
four patients where netilmicin therapy failed. Both od treated patients as well as one tid
treated patient required a second operation despite administration of combination
treatment with antibiotics to which the pathogens were sensitive in vitro. Persistence of
the pathogens could be documented in two patients and a relapse in the third patient.
In another tid treated patient the netilmicin susceptible pathogens causing the
intraabdominal infection were never eradicated over a two week period of treatment and
the patient died. Persistence of pathogens was documented for two further od-treated
patients, one patient with a clinical outcome which could not be evaluated, the other with
a satisfactory clinical response. Persistence of pathogens was also documented for three
further tid-treated patients, where the clinical outcome could not be evaluated.
Six patients in the od group and five patients in the tid group died, including the above
mentioned tid-treated patient where the pathogen persisted. All deaths but one were
considered to be from underlying diseases, i.e. not caused by clinical failure or by adverse
effects of the antibiotic therapy.
Discussion
In this prospective, randomised study no or only minor differences in toxicity and efficacy
were noticed between od and tid regimens. The clinical relevance of the observed
differences appears to be minimal. Major differences between the two study groups were
limited to pharmacokinetic parameters. It was no surprise to find approximately three
times higher peak concentrations and lower trough levels during once daily dosing.
Half-lives of netilmicin determined between 1 h and 8 h increased during therapy with
tid doses from a mean of 2.75 to a mean of 3.33 h (P < 0.01) whereas no significant increase
occurred with od (rise from 2.84 to 3.03 h). Remarkably long half-lives were determined
between 8 h and 24 h in the od group (mean of 5.7 h, P< 0.01). This relatively slow decline
of serum concentrations might relate to the onset of the gamma-elimination-phase.
Aminoglycosides accumulate in deep compartments, e.g. in the kidney, and are
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released from these compartments at a slow rate over prolonged periods (Schentag et al.,
1977; Wenk, Vozeh & Follath, 1984).
Most in-vitro and in-vivo studies have suggested that once daily dosing of
aminoglycosides might result in better clinical efficacy or lower toxicity. Nevertheless, a
few animal studies have shown superior efficacy with multiple daily dosing (Kapusnik
et al., 1988; Fantin & Carbon, 1990), possibly due to the very short half-lives of
aminoglycosides in small animals (Gerbere/ al., 1986; Vogelman et al., 1988; Potel et al.,
1991) resulting in prolonged periods of subinhibitory concentrations. In contrast, low
serum concentrations were present in patients during od treatment only for limited time
periods. The average half-life calculated from peak and trough levels during the 24 h
dosing intervals was more than 4 h.
Higher peak and lower trough levels have been achieved with the od regimen compared
to thrice daily dosing. The need for higher peaks has been advocated because of
concentration-dependent bacterial killing by aminoglycosides and the correlation of
therapeutic outcome with the ratio of peak concentration to susceptibility of the pathogen
(Blaser et al., 1987; Moore, Lietman & Smith, 1987). A prolonged period of subinhibitory
aminoglycoside concentrations might be acceptable for combined treatment with a
/?-lactam antibiotic and also because of the presence of a postantibiotic effect after
exposure to high aminoglycoside concentrations (Vogelman et al., 1988). Concern about
toxicity induced by high serum concentrations of a od aminoglycoside regimen has
restricted its clinical use. However, the prolonged period with relatively low serum
concentrations towards the end of the 24 h dosing interval may greatly reduce the danger
of drug accumulation, thereby reducing the risk of ototoxic and nephrotoxic reactions
(Gilbert, 1991).
This study and previously published clinical trials have not yet shown convincingly
either better efficacy or lower toxicity with od dosing, except for one study demonstrating
significantly lower nephrotoxicity of gentamicin (Prins et al., 1993). However, large
numbers of patients are required to exclude a high risk for false-negative results. This is
particularly true for the assessment of efficacy in heterogeneous study groups. Patients
enrolled in most aminoglycoside dosing trials suffered from a great variety of different
infections and pathogens as well as underlying diseases. Furthermore, clinical response
is a consequence of combination therapy and, in many instances, surgical interventions.
To assess in a quantitative and indisputable manner the contribution of od and tid
aminoglycoside therapy for achieving bacteriological and clinical cure, a treatment group
without any aminoglycoside therapy should be included, which might rise ethical
concerns, and the randomisation procedure should stratify for various above mentioned
factors, which would require for a study with patient numbers beyond the scope of most
investigators.
Although no significant differences have been demonstrated in the present study
between both parameters of toxicity and both parameters of efficacy, all four par-
ameters studied were in favour of once daily dosing. In addition, once daily dosing is
preferable from an economical point of view. Expanding the dosing interval reduces the
risk of drug accumulation. Therefore, serum level monitoring becomes less important
during od therapy of aminoglycosides and fewer blood specimens have to be processed
(Blaser et al., 1994; Parker & Davey, 1993). Thus, reducing the frequency of dosing to
only once a day allows for considerable savings of both manpower and material. The
data gathered in this study suggest that such saving would not be against the interest of
the patients.
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